A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.
- Submitting institution
-
University of Cambridge
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 2944
- Type
- D - Journal article
- DOI
-
10.1126/scitranslmed.aad3744
- Title of journal
- Sci Transl Med
- Article number
- ARTN 341ra76
- First page
- 341ra76
- Volume
- 8
- Issue
- 341
- ISSN
- 1946-6242
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
149
- Research group(s)
-
-
- Citation count
- 53
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The researcher submitted to REF made a substantial contribution to carrying out the study. The researcher also critiqued the output for important intellectual content.
- Non-English
- No
- English abstract
- -